GSK agrees to acquire Nuvalent for $10.6 bln, expects third-quarter close
MLex Summary: London-based GSK agreed to acquire Boston-based Nuvalent, a clinical-stage biopharmaceutical company focused on creating targeted oncology therapies, for $10.6 billion. The deal includes multi-product oncology assets with validated targets that...To view the full article, register now.
Already a subscriber? Click here to view full article